Pfizer announced plans to increase the price of its COVID-19 vaccine to approximately $120 per dose once federal government purchasing ends. This coincides with the emergence of a "tripledemic," a term used by the New York Times to describe the simultaneous rise of COVID-19, the flu, and RSV. Hospitals in 43 states are reportedly facing a surge in respiratory illnesses, particularly among children under five.
